NasdaqGS:BEAMBiotechs
How Beam’s Wider Q2 Loss and Trial Progress Will Impact Beam Therapeutics (BEAM) Investors
Beam Therapeutics recently reported second-quarter 2026 results showing a wider net loss of US$122.68 million and a basic loss per share of US$1.18, alongside a sharp revenue shortfall versus analyst expectations.
At the same time, the company marked important clinical milestones in its genome-editing pipeline, including completing dosing in its risto-cel sickle cell trial and dosing the first patient in the pivotal BEAM-302 study for alpha-1 antitrypsin deficiency.
Now we’ll examine how the...